公开(公告)号：US20250115665A1

公开(公告)日：2025-04-10

申请号：US18833261

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Minh H. DINH ,  Mariana C. STIRNER ,  Iliana E. SZAFER-GLUSMAN

IPC: C07K16/28 ,  A61K31/454 ,  A61K31/519 ,  A61K39/00 ,  A61P35/00

Abstract: Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.

公开(公告)号：US20250101102A1

公开(公告)日：2025-03-27

申请号：US18833267

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Mariana C. STIRNER ,  Minh H. DINH ,  Iliana E. SZAFER-GLUSMAN

IPC: C07K16/28 ,  A61K31/573 ,  A61K39/00 ,  A61P35/00

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).